A Randomised, Single-blind, Placebo-controlled, Single-centre, Phase I Study in Abdominally Obese Healthy Volunteers to Evaluate Methods to Assess 11-beta-HSD1 Activity in Adipose Tissue and Related Downstream Biomarkers After Single and Repeated Oral Doses of AZD4017 for 10 Days.
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2010
At a glance
- Drugs AZD 4017 (Primary)
- Indications Obesity
- Focus Biomarker; Pharmacodynamics
- 27 Sep 2010 Planned end date changed from 1 May 2010 to 1 May 2010 as reported by ClinicalTrials.gov.
- 27 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Apr 2010 New trial record